2019•European Urology SupplementsRequires access

Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis

Suzan Feyerabend, Fred Saad, Tetsufumi Ito, Joris Diels, Suzy Van Sanden, Peter De Porre, Julie Roïz, Ṣẹ̀yẹ Abògúnr̀in, Maria Koufopoulou, Karim S. Fizazi

Open publisher page 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Abiraterone acetate, Medicine, Docetaxel, Prednisone, Oncology, Prostate cancer, Abiraterone, Internal medicine